In brief: Narhex, Norwood Abbey, Anadis, Phylogica
Thursday, 02 February, 2006
Narhex Life Sciences (ASX:NLS) has signed a manufacturing contract with Indian, Nasdaq-listed company Dr Reddy's for initial GMP-grade production of the prodrug of Narhex's candidate HIV protease inhibitor, DG35.
Norwood Abbey (ASX:NAL) has begun animal studies for the application of its needle-free injection device for the delivery of a drug to treat arthritis at Massachusetts Institute of Technology (MIT). The MIT studies will also extend to a range of other applications involving delivery of drugs into joints.
Anadis (ASX:ANX) is to chase opportunities in the international market of high-profile sporting organisations, including athletes preparing for competition in the Beijing Olympics in 2008, following the successful analysis that its over-the-counter travellers' diarrhoea product Travelan does not contain any prohibited substances.
Phylogica (ASX:PYC) has secured a European patent for a new high-level drug-screening technique for isolating Phylomer and other drug candidates that block protein interactions involved in disease. Phylogica is developing drugs based on phylomers -- short-chain, bioactive peptides derived from the highly specialised proteins of extremophile microbes.
Heart muscle regeneration genes mapped
Researchers have uncovered insights into how stem cells develop and mature into heart muscle...
The cause of 2022's mpox outbreak revealed
Researchers have discovered that the strain of mpox behind the 2022 outbreak was a weakened form...
New gene therapy treats liver disorder in growing children
Researchers have developed a genome-editing approach that repairs a faulty gene directly at its...
